» Articles » PMID: 37441466

Managing Hyperkalemia in the Modern Era: A Case-Based Approach

Overview
Journal Kidney Int Rep
Publisher Elsevier
Specialty Nephrology
Date 2023 Jul 13
PMID 37441466
Authors
Affiliations
Soon will be listed here.
Abstract

The last decade has seen tremendous advances in the prevention and treatment of recurrent hyperkalemia. In this narrative review, we aim to highlight contemporary data on key areas in the epidemiology and management of hyperkalemia. Focusing on drug-induced hyperkalemia (the implications of renin-angiotensin-aldosterone system inhibitors [RAASi] discontinuation and the role of mineralocorticoid receptor antagonists), newer concurrent therapies that modify potassium handling (sodium-glucose transporter 2 inhibitors [SGLT2i]), the introduction of new treatment agents (oral potassium binding agents), and the controversial role of dietary potassium restriction, we apply recent research findings and review the evidence in a case-based format.

Citing Articles

Hyperkalemia management: a multidisciplinary expert panel's perspective on the role of new potassium binders.

Fonseca C, Garagarza C, Silva G, Caires G, Marques I, Antonio Lopes J Heart Fail Rev. 2024; 30(2):271-286.

PMID: 39604607 PMC: 11802687. DOI: 10.1007/s10741-024-10461-3.

References
1.
Adrogue H, Madias N . Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981; 71(3):456-67. DOI: 10.1016/0002-9343(81)90182-0. View

2.
Mathialahan T, Sandle G . Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease. Nephrol Dial Transplant. 2003; 18(2):341-7. DOI: 10.1093/ndt/18.2.341. View

3.
Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

4.
Chung E, Ruospo M, Natale P, Bolignano D, Navaneethan S, Palmer S . Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020; 10:CD007004. PMC: 8094274. DOI: 10.1002/14651858.CD007004.pub4. View

5.
Sumida K, Dashputre A, Potukuchi P, Thomas F, Obi Y, Molnar M . Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. J Am Soc Nephrol. 2021; 32(4):950-959. PMC: 8017552. DOI: 10.1681/ASN.2020081120. View